Skip to main content
Erschienen in: World Journal of Urology 4/2018

17.01.2018 | Original Article

Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma

verfasst von: Aditya Bagrodia, Samuel Kaffenberger, Andrew Winer, Katie Murray, Michael Vacchio, Junting Zheng, Irina Ostrovnaya, Bernard H. Bochner, Guido Dalbagni, Eugene K. Cha, Jonathan A. Coleman

Erschienen in: World Journal of Urology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the impact of timing of blood transfusion in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU).

Methods

Outcomes of consecutive patients with UTUC treated with RNU were analyzed. Clinicopathologic factors were compared using Fisher’s exact test or the Wilcoxon rank-sum test between patients who received any transfusion and no transfusion, and between patients receiving intraoperative transfusion only and patients receiving no transfusion. Cancer-specific and overall survival were estimated and multivariable analyses were performed to assess the impact of timing of transfusion on clinical outcomes.

Results

Among 402 patients included in this study, 71 (17.6%) patients received a transfusion at any point and 27 (6.7%) patients received an intraoperative blood transfusion. Transfusion at any time, patient comorbidity, high grade, advanced stage, positive surgical margins, low preoperative hemoglobin, longer operative duration, and increased blood loss were significantly associated with cancer-specific survival (DSS) on univariable analysis (HR 1.85, 95% CI 1.20–2.85, p < 0.005). In the multivariable analysis, transfusion at any point was not a prognostic factor (HR 1.00, 95% CI 0.60–1.68, p = 0.99). When examining intraoperatively transfusion only, transfusion was significantly associated with DSS (HR 1.91, 95% CI 1.01–3.59, p = 0.045) but no longer significant in multivariable analysis (HR 0.72, 95% CI 0.32–1.65, p = 0.440).

Conclusions

Our study indicates that the administration of blood transfusion either intraoperatively or postoperatively is not associated with clinical or oncological outcomes in patients with upper tract urothelial carcinoma when adjusted for other factors in multivariable analysis. Further study is required.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Adibi M, Youssef R, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI et al (2012) Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol 19(12):1060–1066CrossRefPubMed Adibi M, Youssef R, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI et al (2012) Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol 19(12):1060–1066CrossRefPubMed
2.
Zurück zum Zitat Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115(6):1224–1233CrossRefPubMed Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115(6):1224–1233CrossRefPubMed
3.
Zurück zum Zitat Roupret M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR et al (2013) Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol 189(5):1662–1669CrossRefPubMed Roupret M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR et al (2013) Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol 189(5):1662–1669CrossRefPubMed
4.
Zurück zum Zitat Seisen T, Krasnow RE, Bellmunt J, Roupret M, Leow JJ, Lipsitz SR et al (2017) Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol 35(8):852–860CrossRefPubMed Seisen T, Krasnow RE, Bellmunt J, Roupret M, Leow JJ, Lipsitz SR et al (2017) Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol 35(8):852–860CrossRefPubMed
5.
Zurück zum Zitat Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Khalil D, Kapur P et al (2014) Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: results of a current series and a review of the literature. Urol Oncol 32(1):54e19-26CrossRef Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Khalil D, Kapur P et al (2014) Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: results of a current series and a review of the literature. Urol Oncol 32(1):54e19-26CrossRef
6.
Zurück zum Zitat Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, Shariat SF et al (2011) Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 60(4):776–783CrossRefPubMed Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, Shariat SF et al (2011) Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 60(4):776–783CrossRefPubMed
7.
Zurück zum Zitat Rink M, Sharifi N, Fritsche HM, Aziz A, Miller F, Kluth LA et al (2014) Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 191(2):316–322CrossRefPubMed Rink M, Sharifi N, Fritsche HM, Aziz A, Miller F, Kluth LA et al (2014) Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 191(2):316–322CrossRefPubMed
8.
Zurück zum Zitat Rieken M, Schubert T, Xylinas E, Kluth L, Roupret M, Trinh QD et al (2014) Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol 40(12):1693–1699CrossRefPubMed Rieken M, Schubert T, Xylinas E, Kluth L, Roupret M, Trinh QD et al (2014) Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol 40(12):1693–1699CrossRefPubMed
9.
Zurück zum Zitat Rink M, Soave A, Dahlem R, Aziz A, Al-Sayed F, Peine S et al (2016) Impact of perioperative allogenic blood transfusion on survival after radical nephroureterectomy for upper tract urothelial carcinoma. Clin Genitourin Cancer 14(1):96–104CrossRefPubMed Rink M, Soave A, Dahlem R, Aziz A, Al-Sayed F, Peine S et al (2016) Impact of perioperative allogenic blood transfusion on survival after radical nephroureterectomy for upper tract urothelial carcinoma. Clin Genitourin Cancer 14(1):96–104CrossRefPubMed
10.
Zurück zum Zitat Abel EJ, Linder BJ, Bauman TM, Bauer RM, Thompson RH, Thapa P et al (2014) Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol 66(6):1139–1147CrossRefPubMed Abel EJ, Linder BJ, Bauman TM, Bauer RM, Thompson RH, Thapa P et al (2014) Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol 66(6):1139–1147CrossRefPubMed
11.
Zurück zum Zitat Linder BJ, Frank I, Cheville JC, Tollefson MK, Thompson RH, Tarrell RF et al (2013) The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 63(5):839–845CrossRefPubMed Linder BJ, Frank I, Cheville JC, Tollefson MK, Thompson RH, Tarrell RF et al (2013) The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 63(5):839–845CrossRefPubMed
12.
Zurück zum Zitat Morgan TM, Barocas DA, Chang SS, Phillips SE, Salem S, Clark PE et al (2013) The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol 31(6):871–877CrossRefPubMed Morgan TM, Barocas DA, Chang SS, Phillips SE, Salem S, Clark PE et al (2013) The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol 31(6):871–877CrossRefPubMed
13.
Zurück zum Zitat Vamvakas EC, Blajchman MA (2007) Transfusion-related immunomodulation (TRIM): an update. Blood Rev 21(6):327–348CrossRefPubMed Vamvakas EC, Blajchman MA (2007) Transfusion-related immunomodulation (TRIM): an update. Blood Rev 21(6):327–348CrossRefPubMed
14.
Zurück zum Zitat Pesta M, Fichtl J, Kulda V, Topolcan O, Treska V (2013) Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Anticancer Res 33(5):2239–2243PubMed Pesta M, Fichtl J, Kulda V, Topolcan O, Treska V (2013) Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Anticancer Res 33(5):2239–2243PubMed
15.
Zurück zum Zitat Vamvakas EC (1996) Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 36(2):175–186CrossRefPubMed Vamvakas EC (1996) Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 36(2):175–186CrossRefPubMed
Metadaten
Titel
Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma
verfasst von
Aditya Bagrodia
Samuel Kaffenberger
Andrew Winer
Katie Murray
Michael Vacchio
Junting Zheng
Irina Ostrovnaya
Bernard H. Bochner
Guido Dalbagni
Eugene K. Cha
Jonathan A. Coleman
Publikationsdatum
17.01.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 4/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2180-3

Weitere Artikel der Ausgabe 4/2018

World Journal of Urology 4/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.